Physician profile
Azmat Iqbal
NPI 1669490314
$10,223.49
in general payments reported to CMS, 2019-2025
30 companies · $438 in 2025
The $438 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,407 · 2020: $826 · 2021: $1,430 · 2022: $1,143 · 2023: $516 · 2024: $462 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.72 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,642.22 | 2019-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $1,060.92 | 2019-2024 | Tagrisso, Airsupra |
| Pfizer INC. | $672.89 | 2019-2024 | |
| Glaxosmithkline, LLC. | $426.58 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Lilly USA, LLC | $415.84 | 2019-2025 | Verzenio |
| Janssen Biotech, INC. | $388.18 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $382.37 | 2019-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $344.61 | 2019-2024 | |
| Athenex Pharmaceutical Division, LLC | $278.45 | 2019 | |
| Dova Pharmaceuticals | $195.75 | 2020-2021 | |
| Gilead Sciences, INC. | $168.47 | 2022-2024 | Trodelvy |
| Taiho Oncology, INC. | $155.84 | 2022-2025 | |
| Puma Biotechnology, INC. | $125.93 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.98 | 2025 | |
| Array Biopharma INC | $107.37 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $98.81 | 2021-2023 | Tukysa |
| Abbott Laboratories | $98.81 | 2021 | |
| Merck Sharp & Dohme LLC | $93.74 | 2019-2022 | |
| Philips North America LLC | $90.00 | 2022 | |
| Celgene Corporation | $67.13 | 2019-2024 | |
| Ucb, INC. | $50.30 | 2021 | |
| Daiichi Sankyo INC. | $46.00 | 2019-2020 | |
| Global Blood Therapeutics, INC. | $42.46 | 2020 | |
| Amgen INC. | $24.63 | 2019 | |
| Acadia Pharmaceuticals INC | $23.81 | 2020 | |
| G1 Therapeutics, INC. | $23.40 | 2023 | Cosela |
| Genzyme Corporation | $22.05 | 2019 | |
| Exact Sciences Corporation | $21.46 | 2024 | Cologuard Collection Kit |
| Qiagen, LLC | $15.52 | 2021 | |
| Verastem, INC. | $14.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azmat Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.